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ABSTRACT
ARQ 197-215 was a randomized placebo-controlled phase II study testing the 
MET inhibitor tivantinib in second-line hepatocellular carcinoma (HCC) patients. It 
identified tumor MET as a key biomarker in HCC. 
Aim of this research was to study the prognostic and predictive value of 
tumor (MET, the receptor tyrosine kinase encoded by the homonymous MNNG-HOS 
transforming gene) and circulating (MET, hepatocyte growth factor [HGF], alpha-
fetoprotein [AFP], vascular endothelial growth factor [VEGF]) biomarkers in second-
line HCC. Tumor MET-High status was centrally assessed by immunohistochemistry. 
Circulating biomarkers were centrally analyzed on serum samples collected at baseline 
and every 4-8 weeks, using medians as cut-off to determine High/Low status. Tumor 
MET, tested in 77 patients, was more frequently High after (82%) versus before 
(40%) sorafenib. A significant interaction (p = 0.04) between tivantinib and baseline 
tumor MET in terms of survival was observed. Baseline circulating MET and HGF (102 
patients) High status correlated with shorter survival (HR 0.61, p = 0.03, and HR 0.60, 
p = 0.02, respectively), while the association between AFP (104 patients) or VEGF 
(103 patients) status and survival was non-significant. 
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INTRODUCTION
Hepatocellular carcinoma (HCC) is among the 
leading causes of cancer-related death [1], and sorafenib 
is the only approved systemic agent for patients with 
unresectable disease [2, 3]. Identifying biomarkers that 
can predict treatment efficacy will help select additional 
therapeutic strategies [4, 5]. 
The MNNG-HOS transforming gene (MET) 
encoding the receptor tyrosine kinase for hepatocyte 
growth factor (HGF) is involved in cancer progression 
and metastasis formation, and suggests poor prognosis in 
early stage and second-line HCC patients [6-8]. Hypoxia 
and oxidative stress can trigger MET expression or 
activation in HCC, and MET is involved in the resistance 
to antiangiogenic therapy [6, 7, 9, 10], its expression 
increasing in HCC cells resistant to sorafenib [11, 12]. 
MET can even self-activate and be HGF independent [13]. 
MET is also involved in the immune system development 
and bone marrow maturation [14, 15].
Tivantinib is an oral, ATP-independent inhibitor of 
MET, binding to its inactive form [16, 17]; its anti-MET 
effect was confirmed by several groups, though some 
also suggested additional targets [18-20], including a 
weak non-specific anti-tubulin activity [21-23]. However, 
neurotoxicity, a hallmark of tubulin inhibitors, has not 
been reported in over 2000 patients treated with tivantinib 
to date, even at doses much higher than the therapeutic 
one [8, 24-28]. Therefore, tivantinib may have additional 
targets, though these have yet to be confirmed. Tumor 
MET levels have been shown to decrease in both mice 
and patients treated with tivantinib [17, 29]. In clinical 
trials, tivantinib showed significant activity in patients 
with MET-High tumors such as non-squamous non-small 
cell lung cancer (NSCLC), colorectal cancer, HCC, and 
androgen-resistant metastatic prostate cancer [8, 27, 28, 
30, 31]. In contrast, a study in MET-Low breast cancer 
patients showed no response to tivantinib [32].
Following promising phase I study results with 
tivantinib as monotherapy and in combination with 
sorafenib in HCC [26, 33], the ARQ 197-215 randomized, 
placebo-controlled phase II study with tivantinib (2:1 
randomization to tivantinib or placebo) was conducted 
in 107 HCC patients (71 on tivantinib, 36 on placebo) 
pretreated with systemic therapy. Informed consent in 
writing was obtained from each patient and the study 
protocol conformed to the ethical guidelines of the 1975 
Declaration of Helsinki as reflected in a priori approval by 
the appropriate Institutional review committee. The study 
reached its primary endpoint of time to progression in the 
intent-to-treat population and all pre-specified secondary 
efficacy endpoints in MET-High patients. Exploratory 
endpoints included the relationship between biomarkers 
and key efficacy endpoints [8]. 
Considering the lack of accepted biomarkers in 
HCC and realizing the necessity of placebo-controlled 
studies, we analyzed the prognostic and predictive values 
of tumor (MET) and circulating (MET, HGF, alpha-
fetoprotein (AFP), vascular endothelial growth factor 
(VEGF)) biomarkers in the ARQ 197-215 study.
RESULTS
Tumor MET
Tumor samples of sufficient quality for tumor MET 
analysis at immunohistochemistry (IHC) were submitted 
for a total of 77 patients, 49 who were randomized 
to tivantinib and 28 to placebo [8]. Patient baseline 
characteristics were generally balanced between groups 
(Table 1).
When distributing patients by H-score, the 
difference between MET-High and -Low patients was 
clear, with median H-score of 175 in MET-High and 40 in 
MET-Low patients. Approximately half the patients (48%) 
were found to be MET-High. Biopsy date was known for 
72 samples. When samples were analyzed with respect to 
prior therapy, the chance of being MET-High was 40% if 
the biopsy was obtained before sorafenib (N = 55), and 
82% if obtained after sorafenib (N = 17; Table 2). 
As previously published, tumor MET was found 
to have a prognostic role. For patients receiving placebo, 
survival was longer for MET-Low patients than MET-
High patients (HR 0.34, p = 0.02; Figure 1a). MET-High 
expression correlated with tivantinib efficacy (overall 
survival (OS): hazard ratio [HR] 0.38, 95% confidence 
intervals (CI) 0.18-0.81, p = 0.01). Tivantinib was 
ineffective in patients with MET-Low tumors (Figure 1b) 
[8].
Interestingly, no significant difference was found 
between survival of MET-Low patients on placebo and 
MET-High patients on tivantinib (HR 0.72, 95% CI, 
0.30-1.70, p = 0.45), suggesting that tivantinib may offset 
the negative prognostic impact of high MET expression 
(Figure 1c). 
The test for interaction between treatment and MET 
status showed a statistical significance at an alpha level 
of 0.05 for OS (p = 0.04). Correlation between MET and 
Conclusions: Tumor MET levels were higher in patients treated with sorafenib. 
Circulating biomarkers such as MET and HGF may be prognostic in second-line HCC. 
These results need to be confirmed in larger randomized clinical trials.
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Figure 1: Kaplan-Meier analysis of overall survival by tumor MET. 1a. placebo patients by tumor MET status*. 1b. tivantinib 
versus placebo in MET-Low patients. 1c. placebo MET-Low versus tivantinib MET-High patients. *Figure reprinted and adapted from 
(Rimassa et al, Hepat Oncol 2014), with permission from Future Medicine.
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other baseline characteristics was not detected except for 
a slight overlap between MET-High patients and patients 
with a baseline AFP higher than the median.
Circulating MET
The prognostic and predictive values of circulating 
MET were studied in 102 patients (N = 68 on tivantinib, 
N = 34 on placebo). The median MET concentration at 
baseline was 13.26 ng/mL, with a range of 1.29-49.8 ng/
mL. Eighty-six patients (N = 56 on tivantinib, N = 30 
on placebo) who were evaluable for survival were also 
evaluable for changes in circulating MET over the course 
of the study. Baseline characteristics were generally 
balanced between groups, except for higher prevalence of 
hepatitis C virus (HCV) infection (56.9% versus 33.3%, 
Figure 2: Kaplan-Meier analysis of overall survival by circulating MET. 2a. overall population by baseline circulating 
MET status. 2b. placebo patients by baseline circulating MET status. 2c. tivantinib versus placebo in circulating MET-High patients. 2d. 
tivantinib versus placebo in circulating MET-Low patients. 2e. tivantinib patients by best change in circulating MET. 2f: placebo patients 
by best change in circulating MET. 
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p = 0.03) in the circulating MET-High compared to the 
MET-Low group (Table 1). No correlation was found 
between circulating MET and tumor MET status.
Overall, circulating MET-Low patients survived 
longer than MET-High patients (HR 0.61, 95% CI, 0.39-
0.94, p = 0.03; Figure 2a). When analyzing such results 
by treatment arm, a significant difference in terms of OS 
was observed in patients on placebo: 3.8 months in 15 
circulating MET-High and 9.4 months in 19 circulating 
MET-Low patients (HR 0.42, 95% CI, 0.20-0.91, p = 0.02; 
Figure 2b). Survival in circulating MET-High patients 
was 7.0 months on tivantinib (N = 36) and 3.8 months 
on placebo (N = 15), (HR 0.55, 95% CI, 0.28-1.06, p = 
0.07). The OS in circulating MET-Low patients was 7.5 
months on tivantinib (N = 32) and 9.4 months on placebo 
(N = 19), (HR 0.97, 95% CI, 0.51-1.85, p = 0.93; Figures 
2c and 2d). However, the test for interaction between 
circulating MET values and treatment was not significant. 
Patients on tivantinib whose circulating MET 
dropped by at least 10% survived longer than patients with 
no pharmacodynamic response, with a median OS of 13.3 
and 6.3 months, respectively (HR 0.46, 95% CI, 0.24-0.86, 
p = 0.01; Figure 2e). Applying the landmark method in 
which no subject died before 8 weeks, results remained 
unchanged (HR 0.46, 95% CI, 0.24-0.86, p = 0.01). Such 
an advantage was evident by week 8 of therapy (OS 13.3 
months in 21 patients with MET reduction, 6.5 months in 
35 patients with no or minimal MET reduction; HR 0.44, 
Figure 3: Kaplan-Meier analysis of overall survival by circulating HGF. 3a. overall population by baseline circulating HGF 
status. 3b. overall population by best change in circulating HGF.
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95% CI, 0.23-0.86, p = 0.01). No such trend was observed 
in patients receiving placebo (Figure 2f). Furthermore, in 
patients with stable disease at the first tumor assessment, 
median change from baseline MET was -37.9% (std = 
92.3, mean = 6.9, min = -75.8, max = 301.1) on tivantinib, 
+18.4% (std = 112.4, mean = 41.7, min = -89.0, max = 
242.1) on placebo. 
Circulating HGF
The prognostic and predictive values of circulating 
HGF were evaluated in 102 patients (N = 68 on 
tivantinib, N = 34 on placebo). The baseline median HGF 
concentration was 2307 pg/mL, with range of 421-58080 
pg/mL. Eighty-six patients (N = 56 on tivantinib, N = 30 
on placebo) who were evaluable for survival were also 
evaluable for changes in circulating HGF over the course 
of the study. Baseline characteristics were generally 
balanced between groups (Table 1). No correlation was 
found between baseline HGF and circulating or tumor 
MET.
Patients with a baseline HGF lower than the median 
survived longer than patients with a higher baseline HGF 
regardless of the therapy (9.0 months versus 5.0 months; 
HR 0.60, 95% CI, 0.39-0.94, p = 0.02; Figure 3a). When 
analyzing such results by treatment arm, a significant 
difference in terms of OS was observed for patients on 
tivantinib (5.2 months in 30 HGF-High patients, 9.3 
months in 38 HGF-Low patients; HR 0.57, 95% CI, 0.33-
0.98, p = 0.04) but not for patients on placebo (4.2 months 
in 21 HGF-High, 9.0 months in 13 HGF-Low patients, HR 
0.80, 95% CI, 0.37-1.73, p = 0.56). Furthermore, the test 
for interaction shows no correlation between HGF and OS 
benefit with tivantinib. 
Patients with a reduction over time by at least 10% 
in circulating HGF survived longer than patients with no 
or minimal reduction (9.8 months versus 6.5 months; HR 
0.60, 95% CI, 0.36-0.98, p = 0.04; Figure 3b). Applying 
the landmark method in which 1 subject who died before 
8 weeks was removed from the analysis, results remained 
substantially unmodified (HR 0.61, 95% CI, 0.37-1.00, p = 
0.05). No difference in OS was observed when comparing 
patients with and without HGF reduction on tivantinib 
(HR 0.68, 95% CI, 0.37-1.26, p = 0.22) or placebo (HR 
0.48, 95% CI, 0.20-1.10, p = 0.08). In patients with stable 
disease past the first tumor assessment, median change 
from baseline HGF was +28.2% (std = 37.5, mean = 25.0, 
min = -96.6, max = 80.1) regardless of treatment. 
Analysis of outcomes by baseline HGF as well as 
by changes in HGF over the course of the study suggests 
that HGF may correlate with outcome but may not be 
predictive of benefit from tivantinib.
Table 1: Patient baseline characteristics according to biomarker status.
Abbreviations: MET, the receptor tyrosine kinase encoded by the homonymous MNNG-HOS transforming gene; HGF, 
hepatocyte growth factor; AFP, alpha-fetoprotein; VEGF, vascular endothelial growth factor; ECOG PS, Eastern cooperative 
oncology group performance status; HBV, hepatitis B virus; HCV, hepatitis C virus.
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Circulating AFP
Circulating AFP was measured at baseline in 104 
patients, all evaluable for OS (68 on tivantinib, 36 on 
placebo). The baseline median AFP concentration was 
186 IU/mL, with range of 1.5-440008 IU/mL. Baseline 
characteristics were generally balanced between groups 
(Table 1). Correlations between AFP and tumor/circulating 
MET were not meaningful.
A trend towards better outcome was seen in patients 
with a baseline AFP lower than the median, regardless 
of treatment allocation (AFP-Low: N = 52, median OS 
7.8 months; AFP-High: N = 52, median OS 5.0 months; 
HR 0.75, 95% CI, 0.48-1.15, p = 0.18). To understand if 
higher AFP values have a greater prognostic impact, an 
additional analysis was performed using an arbitrary cut-
off value equal to the AFP 75th percentile (third quartile 
(Q3); 3507.50 IU/mL) resulting in longer OS for patients 
with baseline values lower than Q3 (AFP-<Q3: N = 78, 
median OS 7.9 months; AFP-≥Q3: N = 26, median OS 3.0 
months; HR 0.36, 95% CI, 0.22-0.58, p < 0.0001). 
Only 43 patients (31 on tivantinib, 12 on placebo) 
had baseline values ≥20 IU/mL, had samples at multiple 
time points, and were evaluable for OS; therefore, no 
analysis was performed on AFP changes over time. 
Survival of patients on tivantinib versus placebo 
by any AFP status was comparable, with the test for 
interaction resulting non-significant. 
Circulating VEGF
Circulating VEGF was measured in 103 patients 
also evaluable for OS (69 on tivantinib, 34 on placebo). 
Median baseline circulating VEGF was 160 pg/mL. 
Baseline characteristics were generally balanced between 
groups (Table 1). Survival was 9.0 months in patients with 
VEGF-Low (N = 51), 5.0 months in patients with VEGF-
High (N = 52) (HR 0.69, 95% CI, 0.45-1.06, p = 0.09); no 
trend was observed by treatment arm. Survival of patients 
with a VEGF reduction over time by at least 10% tended 
to be longer than survival of patients with no or minimal 
reduction (8.1 months versus 6.8 months; HR 0.78, 95% 
CI, 0.48-1.26, p = 0.31), regardless of treatment. 
DISCUSSION
Prognostic and predictive biomarkers are integral to 
fully understand the disease and to establish efficacious 
treatments in the era of targeted therapies. In HCC, 
retrospective analyses to identify biomarkers have proven 
challenging due to molecular heterogeneity, clonal 
evolution driving drug resistance [34], and the analyses 
being conducted in uncontrolled studies.
The analyses presented here were conducted on data 
from the ARQ 197-215 study of tivantinib in second-line 
HCC, the first placebo-controlled randomized study to 
evaluate a tumor biomarker and to identify biomarkers 
prognostic and predictive of outcome. Although numbers 
for some of the analyzed subgroups were small, the 
population was homogeneous, received sorafenib as prior 
Abbreviations: MET, the receptor tyrosine kinase encoded by the homonymous MNNG-HOS transforming gene; TACE, 
transarterial chemoembolization.
*sampling date available for 72 of the 77 patients. 
aincluding 6 patients treated with TACE; bincluding 1 patient treated with TACE.
Table 2: Tumor MET status by prior therapy.
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systemic therapy, and the analyses had been defined, 
before unblinding, in the statistical analysis plan. 
The prognostic role of tumor MET has been 
previously published, with patients on placebo surviving 
3.8 months if MET-High, and 9.0 months if MET-Low 
[8]. In the current analysis, we observed a dramatic 
difference in MET status between biopsies taken before 
and after sorafenib treatment. This is in line with literature 
suggesting that high MET expression correlates with 
hypoxia, resistance to anti-angiogenic therapies, and poor 
prognosis in HCC [10-12, 35], and further supports the 
prognostic role of MET. A correlation between MET status 
and transarterial chemoembolization (TACE), which also 
causes hypoxia, could not be assessed due to the small 
number of TACE-treated patients in this study (Table 2). 
Our results, confirmed by data from the larger METIV-
HCC study, suggest that biopsies taken after sorafenib 
can more reliably assess the prognostic status of MET in 
second-line HCC patients [36]. Moreover, the weight of 
MET-Low as a positive prognostic factor may have been 
underestimated in the ARQ 197-215 study because MET 
staining was largely assessed on pre-sorafenib samples. 
This also emphasizes the need to biopsy HCC patients 
following sorafenib treatment in order to succeed in 
biomarker research, and to cautiously consider therapeutic 
options based on life expectancy.
In addition, tumor MET was found to be predictive 
of outcome in tivantinib-treated patients with a positive 
interaction test. Comparison of survival curves suggested 
that tivantinib offsets the negative impact of MET, making 
survival of the MET-High treated patients similar to the 
MET-Low population. In the ARQ 197-215 trial, despite 
the high incidence of MET-High status after sorafenib, 
the lack of efficacy of tivantinib in MET-Low patients 
combined with their good prognosis on placebo did not 
allow the overall unselected population to gain a survival 
benefit from tivantinib. The above considerations rely 
on IHC, a technique often criticized for its subjectivity. 
Previously reported studies have employed a relatively low 
cut-off to define MET positivity. As an example, studies 
with rilotumumab defined as MET-High any patient with 
at least 25% of tumor cells staining with any intensity, 
converting to a minimum H-score of 25 for MET-High 
patients [37]. To avoid technique-specific biases, studies 
with tivantinib employed a more conservative reading 
criterion, considering MET-High only samples showing 
both high and diffuse intensity of staining and excluding 
any borderline or slightly positive cases, resulting in a 
minimum H-score of 120 for MET-High patients. Inter-
study variability in defining MET-High status may have an 
impact on the assessment of its prognostic and predictive 
value, and employing a rigorous testing standard allows 
to select the most appropriate population for anti-MET 
therapies.
Publications on circulating biomarkers for second-
line HCC are very limited, the most significant recent 
findings being the possible predictive role of AFP for 
ramucirumab and the potential correlations between 
biomarkers and prognosis, etiology and ethnicity found in 
the EVOLVE-1 trial [38, 39].
In the ARQ 197-215 study, the analyses of 
efficacy endpoints by circulating biomarkers suggested a 
prognostic value for circulating MET and HGF, and a trend 
towards a predictive role only for circulating MET. The 
number of patients did not allow a multivariate analysis to 
exclude the influence of tumor MET on circulating factors, 
therefore such results are to be confirmed in larger studies. 
On the other hand, findings with HGF were in line with 
what was reported for first-line patients in the biomarker 
analysis from the SHARP study [40]. In HCC patients 
pre-treated with sorafenib, AFP was ascribed a prognostic 
role, as confirmed by the BRISK-PS and REACH studies 
[38, 41]. However, in the ARQ 197-215 study, circulating 
MET and HGF provided clearer results than AFP, with a 
similar number of evaluable patients. Median values were 
sufficient to give a statistical survival advantage to patients 
with low levels of either MET or HGF, while lower than 
median AFP only trended towards a better outcome. 
Similar results (data not shown) were obtained with the 
200 and 400 IU/mL cut-off values used in other trials [38, 
42]. Further analysis correlated higher AFP baseline values 
with even shorter survival. 
The pharmacodynamic role of MET was suggested 
by two observations in patients on tivantinib but not 
on placebo: patients who had a reduction over time in 
circulating MET survived longer, as did patients whose 
tumor was stable at first scan and whose circulating MET 
level was reduced from baseline. The observed correlation 
between HGF changes and outcome is in line with data 
demonstrating HGF is produced by active HCC, and 
therefore non-responsive tumors continue to release it into 
the bloodstream [43]. 
The trend towards a role for circulating MET in 
predicting benefit from tivantinib supports the overall use 
of MET as a biomarker in tivantinib studies. However, 
unlike the reported results from the 77 tumor samples 
tested for MET, analysis of OS in relation to baseline 
circulating MET and treatment in the 102 patients did 
not reveal a statistical interaction. Therefore, the power 
of predicting who will respond to tivantinib is greater 
for tumor than circulating MET, and provides rationale 
to use only the former to select patients for clinical trials 
with tivantinib. This is consistent with results previously 
reported in randomized, placebo-controlled studies in 
colorectal, NSCLC, and prostate cancer [27, 28, 30].
Correlations between biomarkers remain 
exploratory, especially considering the study sample 
size. Correlations with tumor MET are difficult to assess 
because many MET-Low results were determined on 
biopsies performed before treatment with sorafenib. 
Correlation between MET and HGF was not expected 
because, as with other receptors, MET could be activated 
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independently [13, 44]. Correlation between MET and 
AFP could not be clearly assessed, since the number 
of patients in whom both were high or low was small 
and either factor could predict aggressive disease 
independently. 
Although the number of patients in the ARQ 197-
215 was relatively small, this remains the only randomized 
clinical trial to date that prospectively evaluated a tumor 
biomarker, and is among the few that evaluated multiple 
circulating biomarkers in HCC. Biological selection of 
patients remains crucial for the development of targeted 
therapies in this population, as demonstrated by the 
general lack of success of phase III studies with unselected 
HCC patients, except for the recent regorafenib study [45]. 
Only recently the REACH study, although negative in the 
overall population, identified AFP as a possible biomarker 
for patient selection for treatment with ramucirumab [38]. 
In conclusion, our analysis suggests baseline 
circulating MET and HGF as prognostic factors in second-
line HCC, and tumor MET as a prognostic and predictive 
biomarker of HCC and tivantinib activity. Given the 
limitations intrinsic in a retrospective analysis from a 
phase II study, results need to be confirmed in larger trials. 
The ongoing METIV-HCC and JET-HCC phase III studies 
of tivantinib in the second-line setting (NCT01755767 and 
NCT02029157) enrolled only patients with tumor MET-
High HCC. Such studies may clarify the role of MET, 
HGF, and AFP in this patient population. 
MATERIALS AND METHODS
Tumor MET
MET expression was evaluated by IHC assay, on 
the most recent sample available, using the CONFIRM™ 
anti-total MET(SP44) antibody (catalog # 7904430, 
Ventana Medical Systems, Tucson, AZ), analyzed 
at an independent Clinical Laboratory Improvement 
Amendments (CLIA) certified laboratory by a board 
certified pathologist after randomization and prior to 
study un-blinding. MET-High was defined as a majority 
(≥50%) of tumor cells with moderate or strong (2+ or 
3+) staining intensity per ArQule’s protocol. A negative 
control slide from each patient sample was run as well 
as positive control from colon adenocarcinoma ensuring 
that proper antibody and reagent dispensing took place. 
Additionally, results of MET testing were reported as an 
H-score, calculated by multiplying the percentage of cells 
staining by the intensity of the stain [46].
Circulating biomarkers
Serum biomarker concentrations were measured by 
ICON Central Labs, Farmingdale, NY, using commercial 
materials.
MET/HGF/VEGF
MET, HGF and VEGF serum samples were 
collected before the first dose on cycle 1 day 1, and post 
dose every 4 weeks thereafter, and at treatment end. One 
blood collection tube was used for MET/HGF testing and 
another for VEGF testing. 
For circulating MET measurement, Kamiya 
Biomedical K-ASSAY Human MET ELISA kit 
(catalog # KT-444), Automated ELISA System (Dynex 
Technologies), and the Spectramax reader (Molecular 
Devices) were used. The Quantikine Human HGF 
Immunoassay (R&D Systems, Minneapolis, MN, catalog 
# SHG00) was used to measure HGF levels in serum using 
the Spectramax reader (Molecular Devices). For VEGF, 
QuantiGlo Human VEGF immunoassay kit from R&D 
(catalog # SVE00) using the Spectramax Plus 384 reader 
was used. 
AFP
AFP serum samples were collected at screening/
pre-study, and every 8 weeks after randomization, as 
well as at the end of treatment. AFP levels were tested 
using automated analyzer Immulite 2000 (kits supplied by 
Siemens Diagnostics, Los Angeles, CA). 
Statistical analysis
All statistical analyses were performed using SAS 
statistical software. Biomarker baseline values and their 
changes over the course of treatment were dichotomized 
and analyzed with respect to OS probability. Median OS 
and the 95% CI were estimated using the Kaplan-Meier 
method and the logrank test was used to compare the 
survival distributions. The Cox regression model was used 
to obtain the HR. The interaction between biomarkers and 
the treatment was evaluated using the Cox proportional 
hazards model with an interaction term. Multivariate 
analysis was not attempted due to the small sample size of 
available biopsies for tumor MET biomarker assessment. 
The correlation between the biomarkers was assessed 
using Fisher’s exact test. The median concentrations of the 
serum baseline biomarkers were used as the cut-off values 
to differentiate the respective Low and High groups for 
the study of prognostic and predictive effects. However, 
in the case of AFP, an additional arbitrary cut-off was set 
at the 75th percentile. As for the changes in biomarker 
concentrations, the best change (highest reduction or 
the lowest increase) during the treatment period for each 
patient was calculated as the percent change from baseline, 
and 10% was arbitrarily chosen as cut-off value. Survival 
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analysis by biomarker reduction was also performed 
restricting the sample to patients who survived to a pre-
specified arbitrary landmark time of 8 weeks after the date 
treatment was started. This latter analysis was specifically 
undertaken to eliminate guarantee-time bias and was 
proposed by others in similar settings [47, 48].
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